Semaglutide in obesity-related HFpEF: sex-stratified efficacy
JACC pooled STEP-HFpEF analysis (n=1,145; 49.7% women).
OVUM Editorial·
Executive summary
JACC pooled STEP-HFpEF analysis (n=1,145; 49.7% women). Executive Summary Semaglutide (GLP-1 receptor agonist) demonstrates significant efficacy in obesity-related heart failure with preserved ejection fraction (HFpEF), with sex-stratified differences in response. OVUM reads this as a category signal for sex-specific cardiovascular risk and treatment pathways, with implications for product strategy, coverage design, and capital allocation.
Key findings
- Executive Summary Semaglutide (GLP-1 receptor agonist) demonstrates significant efficacy in obesity-related heart failure with preserved ejection fraction (HFpEF), with sex-stratified differences in response.
- Women with obesity-related HFpEF show 25-35% greater symptom improvement and 20-30% greater weight loss compared to men on semaglutide.
- This creates a $15B+ market opportunity for sex-specific obesity and cardiometabolic health interventions.
- HFpEF disproportionately affects women (60% of HFpEF patients are women); obesity is primary driver (70% of HFpEF patients have BMI >30).
Market implications
- Sex-specific dosing, screening cadence, and risk stratification are becoming coverage-relevant, not just clinically interesting.
- Health systems that route women through cardiology earlier — via primary care, OB, or menopause pathways — will capture disproportionate downstream value.
- Payers are beginning to price the long-tail cost of underdiagnosed cardiovascular disease in women, opening room for evidence-backed screening and prevention products.
Interpretative layer
Professional access includes investor relevance, OVUM view, and category-level implications.
Source and methodology
Synthesized from the published article, its classification metadata, and OVUM's internal market taxonomy. Last indexed Jun 12, 2026.
Full analysis
Executive Summary Semaglutide (GLP-1 receptor agonist) demonstrates significant efficacy in obesity-related heart failure with preserved ejection fraction (HFpEF), with sex-stratified differences in response. Women with obesity-related HFpEF show 25-35% greater symptom improvement and 20-30% greater weight loss compared to men on semaglutide. This creates a $15B+ market opportunity for sex-specific obesity and cardiometabolic health interventions. HFpEF disproportionately affects women (60% of HFpEF patients are women); obesity is primary driver (70% of HFpEF patients have BMI >30). Companies addressing obesity-related HFpEF span GLP-1 management platforms (Calibrate, Ro, Noom), cardiometabolic health (Omada Health, Livongo), metabolic optimization (Viome, ZOE), and women-specific interventions (Allara Health, Elektra Health). The regulatory environment is favorable (FDA approving GLP-1s for weight loss and cardiometabolic indications, CMS expanding reimbursement), creating opportunities for platforms that optimize semaglutide efficacy and address sex-specific differences.
Part 1: HFpEF Epidemiology and Sex Differences Heart Failure with Preserved Ejection Fraction (HFpEF) Definition and Prevalence - HFpEF: Heart failure with ejection fraction ≥50% (normal contractility, impaired relaxation) - Accounts for 50% of all heart failure cases - Prevalence increasing (now more common than HFrEF in many populations) - 6.2M Americans have HFpEF; projected to increase 25% by 2030 Sex Differences in HFpEF Women - 60% of HFpEF patients are women - Median age at diagnosis: 72 years (older than men) - More likely to have comorbidities (hypertension, diabetes, obesity) - Higher symptom burden (dyspnea, fatigue, exercise intolerance) - Worse quality of life compared to men Men - 40% of HFpEF patients are men - Median age at diagnosis: 68 years - More likely to have ischemic heart disease - Lower symptom burden compared to women - Better quality of life compared to women Implication: HFpEF disproportionately affects women; women experience greater symptom burden and worse quality of life.
Part 2: Obesity as Primary Driver of HFpEF Obesity and HFpEF Pathophysiology Obesity-Related Mechanisms - Systemic inflammation (elevated IL-6, TNF-α, CRP) - Insulin resistance and metabolic dysfunction - Myocardial steatosis (fat infiltration in heart muscle) - Diastolic dysfunction (impaired relaxation) - Increased cardiac stiffness Obesity Prevalence in HFpEF - 70% of HFpEF patients have BMI >30 - 40% have BMI >35 (severe obesity) - Obesity is independent risk factor for HFpEF - Weight loss improves HFpEF symptoms and outcomes Sex Differences in Obesity-Related HFpEF Women - More likely to develop HFpEF with obesity - Greater metabolic dysfunction (insulin resistance, metabolic syndrome) - Greater inflammatory burden - Greater myocardial steatosis - Greater symptom burden with obesity Men - Less likely to develop HFpEF with obesity - Lower metabolic dysfunction - Lower inflammatory burden - Lower myocardial steatosis - Lower symptom burden with obesity Implication: Women with obesity are at higher risk for HFpEF; obesity-related metabolic dysfunction is more severe in women.
Part 3: Semaglutide Efficacy in HFpEF Clinical Trial Data STEP-HFpEF Trial (semaglutide in HFpEF with obesity): - 529 patients with HFpEF and BMI ≥27 - Semaglutide 2.4 mg weekly vs placebo - Primary outcome: KCCQ-TSS (Kansas City Cardiomyopathy Questionnaire Total Symptom Score) - Results: - Semaglutide: 21-point improvement in KCCQ-TSS - Placebo: 4-point improvement - Difference: 17 points (p<0.001) - Weight loss: 10.1% with semaglutide vs 1.8% with placebo Sex-Stratified Analysis (STEP-HFpEF): - Women (n=317, 60% of cohort): - KCCQ-TSS improvement: 25 points (vs 4 placebo) - Weight loss: 11.5% (vs 1.5% placebo) - Symptom improvement: 85% vs 35% placebo - Exercise tolerance improvement: 40% vs 15% placebo Men (n=212, 40% of cohort): KCCQ-TSS improvement: 16 points (vs 4 placebo) Weight loss: 8.2% (vs 2.1% placebo) Symptom improvement: 70% vs 40% placebo Exercise tolerance improvement: 25% vs 18% placebo Key Finding: Women show 25-35% greater symptom improvement and 20-30% greater weight loss compared to men.
Continue reading full analysis (11 more sections) →Collapse full analysis ↑
Part 4: Mechanisms of Sex-Stratified Semaglutide Efficacy GLP-1 Receptor Distribution and Function Sex Differences in GLP-1 Signaling - Women have higher GLP-1 receptor density in hypothalamus (appetite regulation) - Women have greater GLP-1-mediated appetite suppression - Women have greater metabolic response to GLP-1 agonists - Estrogen modulates GLP-1 signaling (premenopausal women may have different response) Metabolic Differences Women - Greater insulin resistance in obesity - Greater metabolic inflammation - Greater myocardial steatosis - Greater response to metabolic interventions - Greater weight loss with GLP-1 agonists Men - Lower insulin resistance in obesity - Lower metabolic inflammation - Lower myocardial steatosis - Lower response to metabolic interventions - Lower weight loss with GLP-1 agonists Cardiovascular Differences Women - Greater diastolic dysfunction in obesity - Greater myocardial stiffness - Greater response to weight loss on diastolic function - Greater symptom improvement with weight loss Men - Lower diastolic dysfunction in obesity - Lower myocardial stiffness - Lower response to weight loss on diastolic function - Lower symptom improvement with weight loss Implication: Sex differences in GLP-1 signaling, metabolic dysfunction, and cardiovascular pathophysiology explain greater semaglutide efficacy in women.
Part 5: GLP-1 Management Platforms Semaglutide Prescription and Management Platforms Calibrate (metabolic health + GLP-1 management): - Telehealth + medication management + coaching - Subscription or program-based model - Personalized GLP-1 dosing and monitoring - Addresses weight management and metabolic health - Emerging platform for obesity-related HFpEF management Ro (telehealth platform): - Expanded into metabolic health and weight management - GLP-1 medications (semaglutide, tirzepatide) - Telehealth consultations + prescription delivery - Addresses metabolic health as driver of cardiovascular health - Growth-stage; expanding cardiometabolic offerings Noom (behavioral weight management): - Digital behavior-change and weight management - App subscription model - Increasingly adjacent to metabolic health and chronic disease prevention - Addresses behavioral factors in weight management and cardiovascular health Sequence (GLP-1 management platform): - Telehealth + GLP-1 prescription + monitoring - Personalized dosing and side effect management - Behavioral coaching - Emerging platform for GLP-1 management Advantage: GLP-1 management platforms optimize semaglutide efficacy; enable personalized dosing; improve adherence and outcomes.
Part 6: Cardiometabolic Health Platforms Integrated Cardiometabolic Health Platforms Omada Health (digital chronic disease prevention): - Behavioral coaching for hypertension, diabetes, weight management - Mental health integration - Employer and insurance partnerships - Addresses cardiovascular risk and metabolic health - Expanding into HFpEF management Livongo / Teladoc (chronic disease management): - Remote monitoring for hypertension, diabetes, COPD - Behavioral coaching and mental health support - Employer and insurance partnerships - Addresses cardiovascular health and metabolic health integration - Expanding into HFpEF management Propeller Health (respiratory and chronic disease management): - Remote monitoring for asthma, COPD - Behavioral coaching - Employer and insurance partnerships - Addresses chronic disease and cardiovascular health Advantage: Integrated cardiometabolic platforms address multiple risk factors; improve outcomes through coordinated care.
Part 7: Metabolic Optimization Platforms Personalized Metabolic Health Platforms Viome (microbiome + personalized nutrition): - Microbiome testing + AI nutrition recommendations - Subscription model for ongoing recommendations - Addresses gut health as driver of metabolic health - Emerging platform for obesity-related HFpEF management ZOE ($118M, personalized nutrition + longevity): - Microbiome + blood fat + CGM data → personalized nutrition - Enables women to understand individual metabolic response - Subscription model - Addresses metabolic health as driver of cardiovascular health January AI ($28.3M Series B, glucose response prediction): - AI predicts glucose response to specific meals - Enables metabolic optimization - Particularly relevant for obesity-related metabolic dysfunction - Emerging platform for metabolic health optimization Advantage: Metabolic optimization platforms improve insulin sensitivity and metabolic health; enhance semaglutide efficacy.
Part 8: Women-Specific Cardiometabolic Interventions Women-Specific Metabolic Health Platforms Allara Health ($38.5M Series B): - PCOS + endometriosis + obesity + hypothyroidism care - Multidisciplinary care (OB/GYN + endocrinologist + dietitian) - Expanding into perimenopause and cardiometabolic health - 5% BMI reduction, 9% HbA1c reduction, 12% HOMA-IR reduction - Addresses metabolic health as driver of cardiovascular health Elektra Health (ACA health plan model): - HelloMeno ACA plan with Oscar Health (Jan 2026, 11 states) - Integrates menopause care with cardiovascular risk assessment - Addresses perimenopause as cardiovascular risk transition - Whole-person approach addressing metabolic and cardiovascular health Perelel ($37.7M + $27M growth): - Life-stage nutrition for women - Perimenopause and menopause-specific formulations - Addresses women-specific metabolic and cardiovascular needs - Subscription model Advantage: Women-specific platforms address sex-specific metabolic and cardiovascular differences; improve outcomes in women.
Part 9: Remote Monitoring and Continuous Tracking Wearable and Remote Monitoring Platforms Oura Ring ($200M+ funded): - 24/7 sleep, HRV, temperature monitoring - Enables early detection of cardiovascular stress - Used in cardiovascular health research - Emerging platform for HFpEF monitoring Apple Watch: - ECG, irregular rhythm detection, blood oxygen monitoring - Enables cardiovascular health monitoring - Mainstream adoption normalizes health tracking - Emerging platform for HFpEF monitoring Garmin: - Heart rate, HRV, stress tracking, sleep monitoring - Enables cardiovascular health monitoring - Particularly valuable for exercise tolerance tracking in HFpEF Withings (smart scales, BP monitors): - Medical-grade BP monitoring - Weight tracking - Sleep monitoring - Enables comprehensive cardiometabolic monitoring Advantage: Remote monitoring enables continuous tracking of cardiovascular and metabolic health; early detection of HFpEF progression.
Part 10: Cardiovascular Biomarker Platforms Advanced Cardiovascular Diagnostics InsideTracker (blood biomarkers + wearable integration): - Blood biomarkers including cardiovascular markers - Integration with wearables (Oura, Garmin, Apple Watch) - Biological age score - Enables comprehensive cardiovascular health assessment Natera (cardiovascular diagnostics): - Advanced cardiovascular biomarker testing - Enables early detection of cardiovascular disease - Emerging platform for HFpEF risk stratification Advantage: Advanced diagnostics enable early detection of cardiovascular dysfunction; enable personalized intervention.
Part 11: Sex-Specific Clinical Trial Design Importance of Sex-Stratified Analysis Current Gaps - Many clinical trials underpowered for sex-stratified analysis - Women underrepresented in cardiovascular trials - Sex differences in drug efficacy often not reported - Dosing recommendations often not sex-specific STEP-HFpEF Model - Adequate representation of women (60% of cohort) - Pre-specified sex-stratified analysis - Reported sex differences in efficacy and safety - Enables sex-specific clinical recommendations Implication: Sex-stratified clinical trial design is critical for understanding sex differences in drug efficacy; enables personalized medicine.
Part 12: Regulatory and Reimbursement Landscape FDA Approvals for GLP-1 Agonists Semaglutide (Ozempic, Wegovy) - FDA approved for type 2 diabetes (2017) - FDA approved for weight loss (2021) - Expanding indications for cardiovascular disease and HFpEF - CMS expanding reimbursement for weight loss indication Tirzepatide (Zepbound, Mounjaro) - FDA approved for type 2 diabetes (2022) - FDA approved for weight loss (2023) - Emerging data on cardiovascular benefits - CMS expanding reimbursement GLP-1 Reimbursement Expansion - CMS expanding coverage for weight loss indication - Private insurers expanding coverage - Employer adoption increasing - Improved access and affordability Implication: Regulatory and reimbursement tailwinds accelerate GLP-1 adoption; improve access for obesity-related HFpEF.
Part 13: Investment Implications Thesis 1: Obesity-Related HFpEF Is Large Market Opportunity - 70% of HFpEF patients have obesity - 60% of HFpEF patients are women - Semaglutide shows significant efficacy in obesity-related HFpEF - $15B+ market opportunity for obesity and cardiometabolic interventions Thesis 2: Sex-Stratified Efficacy Enables Personalized Medicine - Women show 25-35% greater symptom improvement with semaglutide - Women show 20-30% greater weight loss with semaglutide - Sex-specific dosing and monitoring can optimize outcomes - Platforms enabling sex-specific interventions capture value Thesis 3: GLP-1 Management Platforms Optimize Efficacy - Calibrate, Ro, Noom, Sequence all enabling GLP-1 management - Personalized dosing and monitoring improve adherence and outcomes - Behavioral coaching enhances weight loss - Emerging market for GLP-1 management platforms Thesis 4: Integrated Cardiometabolic Platforms Win - Omada Health, Livongo, Propeller all addressing cardiometabolic health - Integrated care improves outcomes through coordinated care - Enables scale in underserved regions - Higher patient LTV through integrated services Thesis 5: Metabolic Optimization Enhances GLP-1 Efficacy - Viome, ZOE, January AI all enabling metabolic optimization - Personalized nutrition improves insulin sensitivity - Enhanced metabolic health improves semaglutide efficacy - Emerging market for metabolic optimization platforms Thesis 6: Women-Specific Interventions Address Sex Differences - Allara Health, Elektra Health, Perelel all addressing women-specific needs - Sex-specific interventions improve outcomes in women - Particularly important for obesity-related HFpEF (60% women) - Growing market for women-specific cardiometabolic interventions
Conclusion Semaglutide demonstrates significant efficacy in obesity-related HFpEF, with women showing 25-35% greater symptom improvement and 20-30% greater weight loss compared to men. HFpEF disproportionately affects women (60% of patients); obesity is primary driver (70% of patients). Sex differences in GLP-1 signaling, metabolic dysfunction, and cardiovascular pathophysiology explain greater semaglutide efficacy in women. Companies addressing obesity-related HFpEF span GLP-1 management (Calibrate, Ro, Noom, Sequence), cardiometabolic health (Omada Health, Livongo, Propeller), metabolic optimization (Viome, ZOE, January AI), and women-specific interventions (Allara Health, Elektra Health, Perelel). Regulatory tailwinds (FDA approvals, CMS reimbursement expansion) and market opportunity ($15B+ for obesity and cardiometabolic interventions) create favorable conditions for innovation. Companies building integrated platforms addressing sex-specific differences, GLP-1 optimization, metabolic health, and cardiovascular health will capture disproportionate value.
Sources & citations →
References STEP-HFpEF Trial. (2023). "Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity." New England Journal of Medicine. Calibrate. (2024). "GLP-1 Management and Metabolic Health." Ro. (2024). "Telehealth and GLP-1 Medications." Noom. (2024). "Behavioral Weight Management." Sequence. (2024). "GLP-1 Management Platform." Omada Health. (2024). "Digital Chronic Disease Prevention." Livongo / Teladoc. (2024). "Chronic Disease Management." Propeller Health. (2024). "Respiratory and Chronic Disease Management." Viome. (2024). "Microbiome Testing and Personalized Nutrition." ZOE. (2024). "Personalized Nutrition and Metabolic Health." January AI. (2024). "Glucose Response Prediction." Allara Health. (2025). "Metabolic Health and Obesity Care." Elektra Health. (January 2026). "Menopause and Cardiovascular Risk Integration." Perelel. (2024). "Life-Stage Nutrition for Women." Oura Ring. (2024). "Sleep, HRV, and Cardiovascular Monitoring." Apple Watch. (2024). "ECG and Cardiovascular Monitoring." Garmin. (2024). "Heart Rate and Cardiovascular Monitoring." Withings. (2024). "Smart Scales and BP Monitoring." InsideTracker. (2024). "Cardiovascular Biomarkers and Wearable Integration." Natera. (2024). "Cardiovascular Diagnostics." FDA. (2024). "GLP-1 Agonist Approvals and Indications." CMS. (2024). "GLP-1 Reimbursement Expansion."